Biochemistry

Sterne Kessler Elects Six New Directors in 2024

Retrieved on: 
Thursday, January 4, 2024
Biology, Senior counsel, Auburn University, Brooklyn Law School, Prior art, Intellectual property, Science, Blockchain, University, Biotechnology, Software, Glass, Research, Physics, Supreme court, Patent, Pennsylvania State University, George Mason University, Freedom, Supreme, Chase, Biochemistry, Data compression, Artificial intelligence, Texas A&M University, Smartphone, Engineering, George, State university system, Lawyer, Virginia Tech, Synthetic biology, PTAB, Information technology, ITC, Pharmaceutical industry

WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox is proud to announce that six attorneys have been elected to the directorship effective January 1, 2024.

Key Points: 
  • WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox is proud to announce that six attorneys have been elected to the directorship effective January 1, 2024.
  • "It is an honor to congratulate our six new directors on this well-deserved milestone.
  • Read more about Sterne Kessler's new directors:
    David W. Haars , is a member of Sterne Kessler's Electronics Practice Group.
  • He regularly represents both complainants and respondents across a wide range of technologies in Section 337 investigations before the ITC.

ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Oncology, Biology, Ipsen, University of Jena, Science, Drug discovery, Autoimmune disease, Autoimmunity, Research, FDA, Disease, Therapy, EZH2, Inflammation, AKT, Biochemistry, PARP, Merck, Patient, Harvard Medical School, History, Pharmaceutical industry

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.
  • Dr. Keilhack brings to ROME more than 20 years of experience leading target validation and preclinical and translational efforts for multiple first-in-class therapeutics at both small biotechnology companies and large pharmaceutical companies.
  • “I was drawn to ROME because of its compelling scientific approach to drug discovery and development, as well as its highly talented team of business and scientific leaders,” said Dr. Keilhack.
  • I am excited to work as part of the ROME team as we uncover and advance this science toward helping patients who need new options.”

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
IO, Biology, Research, Bristol Myers Squibb, Disease, Merck Serono, Therapy, Merkel-cell carcinoma, Cancer, Molecular biology, Master of Science, Novartis, M.A, Biochemistry, Proteomics, Neoplasm, Serono, Merck, Ipilimumab, AP3, Patient, ACRV, Medicine, Phase II, Pharmacology, Pharmaceutical industry

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.
  • “Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “During his impressive career, he has effectively executed on advancing drugs from early development through regulatory approval, at both pharma and biotech companies.
  • Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.

Premier Naturopathic Medical Practice, Nova Clinic, Moves To Roswell, GA, Location

Retrieved on: 
Tuesday, January 2, 2024
Patient, Senior counsel, Multimedia, National university, Chronic pain, Health, Diabetes, Outline of health sciences, Migraine, Metro Area, Emory University, Fertility, Anxiety, Biochemistry, Thyroid, ADD, Psychology, Nature, Pharmaceutical industry

ROSWELL, Ga., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Nova Clinic, a leading naturopathic medical practice, is thrilled to announce its relocation to a state-of-the-art facility on January 1, 2024. The clinic's new address is 1240 Upper Hembree Rd., Suite E, and is conveniently located inside Vita Infusions in Roswell, Georgia. Under the guidance of esteemed naturopathic doctor, Dr. Shama Patel, Nova Clinic has gained a reputation for providing safe, natural and holistic therapies that prioritize patient well-being. The new location at 1240 Upper Hembree Rd., Suite E close to downtown Alpharetta, will allow Nova Clinic to better serve the community and meet the growing demand for alternative medicine. Patients can expect a warm and inviting atmosphere that promotes healing and wellness.

Key Points: 
  • ROSWELL, Ga., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Nova Clinic, a leading naturopathic medical practice , is thrilled to announce its relocation to a state-of-the-art facility on January 1, 2024.
  • Under the guidance of esteemed naturopathic doctor, Dr. Shama Patel, Nova Clinic has gained a reputation for providing safe, natural and holistic therapies that prioritize patient well-being.
  • The new location at 1240 Upper Hembree Rd., Suite E close to downtown Alpharetta, will allow Nova Clinic to better serve the community and meet the growing demand for alternative medicine.
  • Dr. Patel is a member of the American Association of Naturopathic Physicians and the Georgia Association of Naturopathic Physicians.

ChemPartner Unveils Highly Anticipated Biology Database

Retrieved on: 
Friday, December 22, 2023
Biology, Database, Drug discovery, Collection, Drug development, Data analysis, Research, PDX, Literature, Statistics, Biochemistry, CDX, Gene expression, CNS, Genomics, Gene, Pathology, Syngenic, SOC, Mining, Pharmacology, Medical imaging

SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.

Key Points: 
  • SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.
  • The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
  • To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages.
  • The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database.

Hamilton Thorne Appoints Dr. Ekaterina (Kate) Torchilin as President and CEO

Retrieved on: 
Thursday, December 21, 2023
Tufts University, Purification, Software, Biologicals, Research, Acquisition, Cell culture, Cell, Connected health, Vaccine, ART, MBA, Thermo Fisher Scientific, Doctor of Philosophy, Harvard Business School, Health, Biochemistry, Growth, TSX, Patient, HTL, Management

Dr. Torchilin is succeeding David Wolf, who is retiring as President and CEO.

Key Points: 
  • Dr. Torchilin is succeeding David Wolf, who is retiring as President and CEO.
  • Dr. Torchilin will also join the Hamilton Thorne Board of Directors upon assuming the CEO role.
  • Hamilton Thorne Chairman David Wolf said: “We are delighted to welcome Kate as our new Chief Executive at this exciting time in our Company’s development.
  • He will also continue to work actively to develop acquisition initiatives and strategic stakeholder and industry relationships.

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

Retrieved on: 
Wednesday, December 20, 2023
Biology, Partnership, Drug discovery, DNA-binding protein, Matchmaker, Biochemistry, Library, Proteome, REAL, Machine learning, Fine chemical

“We believe combining one of the largest chemical libraries with our protein-ligand predictor tool, MatchMaker, will unlock the ability to generate more powerful compound libraries for drug discovery purposes.”

Key Points: 
  • “We believe combining one of the largest chemical libraries with our protein-ligand predictor tool, MatchMaker, will unlock the ability to generate more powerful compound libraries for drug discovery purposes.”
    “Chemical space is limitless,” said Andrey Tolmachov.
  • From there, Recursion will utilize MatchMaker’s predicted protein-ligand interactions for Enamine REAL Space containing 36B compounds to design compound libraries enriched for molecules that are likely to bind to biological targets.
  • Enamine may offer the resulting libraries to customers for purchase and will co-brand any libraries under both the Enamine and MatchMaker trademarks.
  • Furthermore, Recursion will receive preferential pricing on any enriched screening libraries made available to Enamine customers as part of the collaboration.

Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Retrieved on: 
Monday, December 18, 2023
Associate, MD–PhD, Immunotherapy, Immunology, Autoimmune disease, UTHSC, Biology, Autoimmunity, Research, Drexel University, SLE, APS, Lupus, MD, Amyloidosis, Biochemistry, Genetics, University, LOS, Rheumatoid arthritis, Science Translational Medicine, Patient, Vaccine

LOS ANGELES, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined the Nexcella Scientific Advisory Board.  Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.

Key Points: 
  • Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.
  • I believe recent developments in the CAR-T field allow for novel approaches to treat autoimmune diseases,” said Dr. Radic.
  • “I am excited about joining the Nexcella scientific advisory board and continuing to contribute to expanding treatment options to patients with debilitating autoimmune diseases.”
    "It is a pleasure to welcome Dr. Radic as a member of our Scientific Advisory Board.
  • Prior to joining UTHSC in 2000, Dr. Radic was an Associate Professor in the Department of Microbiology at Drexel University.

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Retrieved on: 
Monday, December 18, 2023
Associate, Immunotherapy, Immunology, Autoimmune disease, UTHSC, Biology, Autoimmunity, Research, Drexel University, SLE, APS, Lupus, MD, Amyloidosis, Biochemistry, Genetics, University, LOS, Rheumatoid arthritis, Science Translational Medicine, Patient, Vaccine

LOS ANGELES, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.

Key Points: 
  • Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.
  • I believe recent developments in the CAR-T field allow for novel approaches to treat autoimmune diseases,” said Dr. Radic.
  • “I am excited about joining the Nexcella scientific advisory board and continuing to contribute to expanding treatment options to patients with debilitating autoimmune diseases.”
    "It is a pleasure to welcome Dr. Radic as a member of our Scientific Advisory Board.
  • Prior to joining UTHSC in 2000, Dr. Radic was an Associate Professor in the Department of Microbiology at Drexel University.

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant

Retrieved on: 
Monday, December 18, 2023
Cytokine, AACR, Immunotherapy, Research, The central science, Vaccine, Molecular biology, Patent, MD, Doctor of Philosophy, Pharmacology, Biochemistry, University, Society, T cell, OTCQB, Physiology, Heat shock protein, RBS, Chemokine, SITC

The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.

Key Points: 
  • The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.
  • Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee.
  • The research underlying the allowed application was led by Dr. Narendran and his lab team (the Narendran Lab).
  • This work also portends the potential benefit of PV-10 in combination with targeted immunotherapies and antibody-drug conjugates for cancer treatment.